PRF1 and neoplasm: Overall, our results demonstrate that CAR-CLDN18.2 γδ T cells can effectively recognize CLDN18.2-positive target tumor cells and secrete high levels of Granzyme-B, Perforin-1, and IFN-γ to exert antitumor effects (Figure 6G).